Vivan Hellström

11PUBLICATIONS
41CO-AUTHORS
Molecular targetsMedical devicesMedia industry studiesPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Apr 29, 2026
Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial.

|Feb 16, 2026
LOAd703-induced tumor microenvironment gene engineering in combination with atezolizumab in metastatic malignant melanoma: a phase I/II trial.

O Hamid, V Ekström-Rydén, I Mehmi

|Dec 12, 2025
Characteristics and overall survival in patients with T1 melanoma: A nationwide matched cohort study.

Ylva Naeser, Rasmus Mikiver, Karolin Isaksson

|Oct 03, 2025
Baseline laboratory values and metastatic burden predict survival in addition to IMDC risk in real-world renal cell carcinoma patients treated with ipilimumab-nivolumab.

Alaa Kheir, Berglind Johannsdottir, Alexandra Grönn-Weiss

|Jan 23, 2025
First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies.

Ana Carneiro, Amanda Hahn, Peter Ellmark

|Jun 28, 2023
Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy.

Vasu R Sah, Henrik Jespersen, Joakim Karlsson

Pageof 2

Frequent Collaborators

4 joint publications

Angelica Loskog

3 joint publications

Jessica Wenthe

3 joint publications

Tanja Lövgren

2 joint publications

Salem Alsaqal